CTX.WAR Captor Therapeutics S.A.
- Market cap
- PLN 348M
- P/E
- -
- P/B
- 5.32x
- ROE
- -70.0%
- Dividend yield
- -
- Fundamental score
- 1.1/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is CTX.WAR undervalued?
Graham numberThe Graham number of Captor Therapeutics S.A. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Captor Therapeutics S.A. fundamental analysis
5 of 21 checks passedROE 0/2
Low return on equity (-70.0%), below 10%.
ROA 0/1
Return on assets (-57.2%) is below the industry median (-18.6%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (7.7%) is above the industry median (2.6%).
Revenue Growth 0/2
Revenue shrank 20.2% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (4.1%), 40% or less.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Cash Runway 1/2
Cash covers 1.4 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (5.5x) is above the industry median (3.6x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Captor Therapeutics S.A. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Captor Therapeutics S.A.
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, develops therapeutic molecules for treating oncological and autoimmune diseases in Poland. The company offers targeted protein degradation technology that utilizes the Optigrade drug discovery platform to overcome the limitations of inhibitors and antibody drugs by destroying disease-causing proteins that are resistant to available therapeutics. It develops viadrudomide, which is in a Phase 1 clinical trial for…
Full company profileCaptor Therapeutics S.A. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Captor Therapeutics S.A. annual financial statements (PLN; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 474K | 16.0K | 0.00 | 1.45M | 3.99M | 9.16M | 13.2M | 15.8M | 4.66M | 3.92M |
| Gross Profit | 379K | -2.57M | -4.46M | -6.60M | 3.25M | 7.07M | 6.90M | 6.42M | -652K | 1.81M |
| Operating Income | -133K | -4.13M | -7.86M | -12.2M | -31.7M | -38.4M | -73.0M | -39.0M | -43.6M | -53.4M |
| EBITDA | 466K | -1.57M | -3.42M | -5.70M | -24.4M | -28.2M | -64.8M | -32.9M | -48.8M | -48.1M |
| Net Income | -180K | -4.42M | -8.74M | -13.1M | -32.6M | -35.9M | -70.6M | -38.4M | -42.0M | -45.5M |
| EPS | -0.06 | -1.36 | -2.68 | -4.02 | -7.89 | -8.61 | -15 | -8.25 | -7.61 | -7.49 |
| Balance Sheet | ||||||||||
| Total Assets | 5.12M | 18.1M | 25.3M | 25.8M | 144M | 113M | 97.3M | 87.5M | 40.0M | 79.5M |
| Total Liabilities | 4.98M | 14.6M | 21.0M | 26.8M | 19.3M | 16.7M | 28.1M | 23.0M | 16.5M | 14.5M |
| Shareholders' Equity | 144K | 3.43M | 4.28M | -1.00M | 124M | 96.3M | 69.2M | 64.5M | 23.5M | 65.1M |
| Cash & Short-term Investments | 1.59M | 2.45M | 12.3M | 10.7M | 118M | 90.9M | 75.7M | 39.3M | 32.1M | 71.5M |
| Total Debt | 2.83M | 10.9M | 10.3M | 12.4M | 8.18M | 6.95M | 3.78M | 5.64M | 3.58M | 2.66M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 2.10M | -2.13M | 4.40M | -595K | -28.5M | -22.9M | -52.2M | -31.9M | -36.3M | -49.2M |
| Capital Expenditure | 0.00 | 100K | 229K | 212K | 5.11M | 892K | 3.01M | 424K | 210K | 470K |
| Free Cash Flow | 2.10M | -2.23M | 4.17M | -807K | -33.6M | -23.8M | -55.2M | -32.1M | -36.5M | -49.6M |
| Ratios | ||||||||||
| ROE | -125.0% | -128.9% | -204.2% | - | -26.2% | -37.3% | -102.0% | -59.6% | -178.9% | -70.0% |
| ROA | -3.5% | -24.5% | -34.5% | -50.8% | -22.7% | -31.8% | -72.5% | -43.9% | -104.9% | -57.2% |
| Net Profit Margin | -38.0% | -27,637.5% | - | -900.1% | -817.2% | -391.9% | -534.7% | -242.8% | -901.2% | -1,160.1% |
| Debt to Equity | 19.68x | 3.16x | 2.40x | - | 0.07x | 0.07x | 0.05x | 0.09x | 0.15x | 0.04x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Captor Therapeutics S.A. dividends
Captor Therapeutics S.A. has not paid dividends in the last 9 fiscal years.
Who owns Captor Therapeutics S.A.
- Insiders 29.27%
- Institutions 32.50%
- Public & others 38.24%
- Shares outstanding 6.33M
- Free float 4.47M
Captor Therapeutics S.A. company profile
- Company name
- Captor Therapeutics S.A.
- Ticker
- CTX.WAR
- ISIN
- PLCPTRT00014
- Exchange
- Warsaw Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 82
- Fiscal year end
- December
- Address
- ul. Dunska 11, Wroclaw, Poland, 54-427
- Phone
- 48 53 786 9089
- Website
- captortherapeutics.com
About Captor Therapeutics S.A.
Captor Therapeutics Spolka Akcyjna, a biopharmaceutical company, develops therapeutic molecules for treating oncological and autoimmune diseases in Poland. The company offers targeted protein degradation technology that utilizes the Optigrade drug discovery platform to overcome the limitations of inhibitors and antibody drugs by destroying disease-causing proteins that are resistant to available therapeutics. It develops viadrudomide, which is in a Phase 1 clinical trial for hepatocellular carcinoma (HCC), lung cancer, and rare cancers; vratitoclax, a bifunctional MCL-1 protein degrader that is in the CTA-enabling stage for liquid and solid tumors; CT-02B, a NEK7 degrader that is in preclinical trials for neuroinflammation indications in Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS); CT-02S, a NEK7 degrader that is in preclinical trials for systemic autoimmunity indications in inflammatory bowel diseases (IBD), gout, and dermatological diseases; and CT-05, a PKCtheta degrader that is in preclinical trials for autoimmunity, transplantation, and metabolism indications. In addition, the company's candidates in the discovery phase include an undisclosed project for oncology, autoimmunity, CNS, and rare indications; and novel E3 ligases for oncology and autoimmunity indications. Captor Therapeutics Spolka Akcyjna was incorporated in 2015 and is headquartered in Wroclaw, Poland.
Captor Therapeutics S.A. management
7- Mr. Michal WalczakCEO, President of Management Board & Chief Scientific Officer
- Mr. Sylvain CottensCo-Founder & Senior VP of Chemistry
- Mr. Adam LukojcCFO & Member of the Management Board
- Ms. Anna PawlukCOO & Member of the Management Board
- Ms. Marta TomaszewskaVice President of People & Culture
- Dr. Thomas Shepherd Ph.D.Senior Vice President of Strategy
- Dr. Adam Ostrowski M.D.Chief Medical Officer